Scientists, doctors, lab directors and other life-science professionals – including several Nobel Prize winners – form the QIAGEN client list. The company advances scientific knowledge by providing the tools to study and analyse the building blocks of life — DNA, RNA and proteins. QIAGEN is also using laboratory developed tests to aid healthcare workers in the coronavirus outbreak. The company emerged as an entrepreneurial offshoot of university research conducted nearly 40 years ago, and in the ensuing four decades has evolved into an enterprise employing 4,700 people across 25 countries. QIAGEN is a leader in the areas of molecular diagnostics. Its differentiated Sample To Insight solutions provide laboratories with specialised products, applications and insights into genetic diseases and cancer treatments such as immunotherapy. QIAGEN views business as a vehicle that can improve quality of life as well as generate profits. As a good corporate citizen, the company has gone beyond compliance to become a trend-setter of sustainable business development. It runs operations in an energy efficient and eco-conscious manner, nurtures a high-performance and healthy work culture, and forges partnerships to spur social and scientific progress. The QIAGEN team feels a strong sense of public duty and goes the extra mile to deliver on its promise to improve lives. The latest innovation is a screening initiative to test for latent tuberculosis – a disease which the World Health Organisation estimates affects one in four people worldwide. The CFI.co judging panel recognises these efforts as a force for positive change, and confers on QIAGEN the 2020 award for Best Life Sciences Corporate Governance (Germany).